Cywinski Jacek B, Mascha Edward J, Kurz Andrea, Sessler Daniel I
Department of General Anesthesiology, Cleveland Clinic, 9500 Euclid Avenue/G31, Cleveland, OH, USA,
Can J Anaesth. 2015 Jul;62(7):745-52. doi: 10.1007/s12630-015-0398-8. Epub 2015 Apr 29.
Serum creatinine is the most commonly used indicator of renal function, but its derivative, estimated glomerular filtration rate (eGFR), has been shown to be superior in non-surgical settings. It remains unknown if eGFR better predicts postoperative mortality in non-cardiac surgical patients. We thus tested the hypothesis that eGFR predicts 30-day mortality after non-cardiac surgery better than serum creatinine.
We evaluated patients who had inpatient non-cardiac surgery of at least one hour duration during January 2006 to December 2011 at the Cleveland Clinic Main Campus and whose preoperative serum creatinine was measured within 30 days before surgery. The eGFR was calculated using the Chronic Kidney Disease-Epidemiology Collaboration equation. Preoperative eGFR was compared in a multivariable analysis with preoperative serum creatinine (both assessed as continuous variables) on the ability to predict 30-day mortality in all patients. Secondarily, the comparison was made within subgroups based on amount of blood loss, blood transfusion, and sex.
There were 92,888 patients included in the final analysis. The eGFR was a modestly better discriminator of 30-day mortality than serum creatinine, with an estimated c-statistic (95% confidence interval) of 0.67 (0.65 to 0.68) for eGFR vs 0.61 (0.59 to 0.63) for serum creatinine (P < 0.001). Furthermore, the eGFR was consistently a better discriminator of 30-day mortality across blood loss, transfusion, and sex groups. Reclassification analyses suggested improved individual predictions of 30-day mortality using eGFR compared with serum creatinine. Nevertheless, a multivariable combination of baseline characteristics of American Society of Anesthesiologists physical status, age, and body mass index (all P < 0.001) discriminated 30-day mortality with a c-statistic of 0.850. Adding eGFR to the model improved the c-statistic to only 0.851, while separately adding serum creatinine did not change the c-statistic.
The eGFR is a modestly better predictor of 30-day mortality than serum creatinine in patients having inpatient non-cardiac surgery. Given that eGFR is often reported by clinical laboratories and is otherwise easy to calculate, it should generally be used in preference to creatinine alone.
血清肌酐是最常用的肾功能指标,但其衍生指标,即估计肾小球滤过率(eGFR),已被证明在非手术环境中更具优势。eGFR是否能更好地预测非心脏手术患者的术后死亡率尚不清楚。因此,我们检验了这一假设:eGFR在预测非心脏手术后30天死亡率方面优于血清肌酐。
我们评估了2006年1月至2011年12月在克利夫兰诊所主院区接受至少持续一小时的住院非心脏手术且术前血清肌酐在手术前30天内测量的患者。使用慢性肾脏病流行病学协作组方程计算eGFR。在多变量分析中,比较术前eGFR和术前血清肌酐(均作为连续变量)预测所有患者30天死亡率的能力。其次,在根据失血量、输血情况和性别划分的亚组内进行比较。
最终分析纳入了92,888例患者。eGFR在区分30天死亡率方面略优于血清肌酐,eGFR的估计c统计量(95%置信区间)为0.67(0.65至0.68),而血清肌酐为0.61(0.59至0.63)(P<0.001)。此外,在失血量、输血情况和性别组中,eGFR始终是区分30天死亡率的更好指标。重新分类分析表明,与血清肌酐相比,使用eGFR可改善对30天死亡率的个体预测。然而,美国麻醉医师协会身体状况、年龄和体重指数的基线特征的多变量组合(所有P<0.001)以0.850的c统计量区分30天死亡率。将eGFR添加到模型中仅将c统计量提高到0.851,而单独添加血清肌酐则未改变c统计量。
在接受住院非心脏手术的患者中,eGFR在预测30天死亡率方面略优于血清肌酐。鉴于临床实验室经常报告eGFR且计算简便,一般应优先于单独使用肌酐。